No, You Cannot Currently Prescribe Wegovy 7.2 mg
The Wegovy 7.2 mg high-dose pen is not yet FDA-approved and therefore cannot be prescribed in clinical practice. The maximum FDA-approved maintenance dose of subcutaneous semaglutide (Wegovy) for weight management remains 2.4 mg once weekly 1.
Current FDA-Approved Dosing
The FDA-approved dosing schedule for Wegovy is 1:
- Initiation: 0.25 mg weekly (weeks 1-4)
- Escalation: 0.5 mg weekly (weeks 5-8) → 1 mg weekly (weeks 9-12) → 1.7 mg weekly (weeks 13-16)
- Maintenance: Either 1.7 mg or 2.4 mg once weekly (week 17 onward), with 2.4 mg being the recommended maintenance dose
The 7.2 mg Dose: Investigational Only
While the 7.2 mg dose shows promising results, it remains in Phase 3b clinical trials 2, 3. The STEP UP trial (published January 2025) demonstrated that semaglutide 7.2 mg achieved superior weight loss compared to 2.4 mg (-18.7% vs -15.6% at 72 weeks), with significantly more participants reaching ≥20% and ≥25% body weight reductions 3. However, this higher dose also showed increased gastrointestinal adverse events (70.8% vs 61.2%) and dysesthesia (22.9% vs 6.0%) compared to the 2.4 mg dose 3.
Clinical Implications
For patients not achieving adequate weight loss on 2.4 mg:
- Ensure proper dose titration was followed (monthly escalation over 16 weeks)
- Verify adherence to the once-weekly schedule
- Confirm concurrent lifestyle intervention (reduced-calorie diet and increased physical activity) 1
- Consider the 1.7 mg maintenance dose may be appropriate for some patients based on tolerability 1
- Evaluate for alternative or adjunctive obesity pharmacotherapy if response remains inadequate
Common Pitfall
Do not attempt to prescribe higher doses by having patients use multiple pens or doses per week. This is off-label, lacks safety data, and violates FDA-approved prescribing guidelines. The 7.2 mg dose requires specific formulation and titration protocols that are still under investigation 3.
Wait for FDA approval of the 7.2 mg formulation before prescribing this dose. Current guidelines from AACE (2025) acknowledge the 7.2 mg dose is "being tested in phase III trials" but do not recommend its use outside of clinical trials 2.